Skip to content
Metabolic peptides

Mazdutide

Mazdutide (IBI362, LY3305677) is an oxyntomodulin-derived peptide that acts on GLP-1 and glucagon receptors. Approved business buyers can apply for wholesale access.

US Peptide Distributors supplies Mazdutide at wholesale to approved business buyers. Every lot is tested by an independent third-party laboratory (we use Freedom Diagnostics and ILS Labs): HPLC for purity and mass spectrometry for identity. Pricing is quoted by supply option: USA stock, USA-synthesized or overseas-sourced, and USA stock offers same-day shipping with no minimum order.

Updated

Synonyms
IBI362, LY3305677, LY-3305677
Formula
C207H317N45O65
Molecular weight
4476 g/mol
CAS number
2259884-03-0

Approved buyers see pricing

Wholesale pricing is available to approved business buyers after they log in.

Supply and testing

  • Every lot third-party testedHPLC for purity, mass spectrometry for identity. Labs: Freedom Diagnostics and ILS Labs.
  • Three supply optionsSupply options for wholesale ordersUSA stock (ships from US inventory), USA-synthesized, overseas-sourced.Ask which options apply to this compound.
  • Same-day shipping on USA stockExpedited options available. Overseas-sourced orders typically take 7-10 days.
  • No minimum on USA stockOne box to thousands of kits, plus gram and kilogram powder.
  • COA in your company nameCan be added to an order and is provided with it.

Distributor programShipping times

Request a quote for Mazdutide

Identity and class

Mazdutide is a synthetic peptide of about 4.5 kDa, registered under the research codes IBI362 and LY3305677. It is described in the literature as a dual agonist of two class B receptors, the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR). A 2026 patent-landscape analysis places it among the oxyntomodulin analogs, with the early peptide design credited to Eli Lilly and later formulation and development work led by Innovent Biologics.

Where it comes from structurally

Oxyntomodulin is an endogenous hormone secreted by the intestine after nutrient intake, and it activates both the GLP-1 and glucagon receptors. A 2023 review of oxyntomodulin-based co-agonists explains the reason analogs exist: the native hormone is short-lived, so medicinal chemists have modified its structure to raise potency and prolong its half-life, and several GLP-1/glucagon dual receptor agonists are now in clinical development. The review focuses on structure-activity relationships, meaning which parts of the sequence govern each receptor interaction.

Oxyntomodulin itself is one member of a family. Proglucagon, a single precursor, is cut by the prohormone convertases PC1/3 and PC2 in a tissue-specific way, yielding glucagon, GLP-1, GLP-2, oxyntomodulin, glicentin and glicentin-related pancreatic peptide. A 2021 review lays out the physiology of that family and describes how dual and triple receptor agonists were designed from it.

What a page like this can and cannot say

The published record on mazdutide includes clinical trials, but this page does not summarise their outcomes. Efficacy conclusions belong in a regulatory or medical setting and not in a supplier's catalogue, and nothing here should be read as a claim about what the compound does in people. For laboratory purposes, the relevant facts are the identity, the receptor targets and the structural lineage described above.

Sourcing notes

Peptides of this size carry modifications that make identity the main analytical question. Check that a certificate gives the observed intact mass and the method used, and that the molecule named matches IBI362 or LY3305677 rather than a related analog. Our guide on research-use-only labeling explains the framework under which this material is supplied.

Supply is for approved business buyers, for laboratory research use only.

References

  1. Zhihong Y, et al. Emerging roles of oxyntomodulin-based glucagon-like peptide-1/glucagon co-agonist analogs in diabetes and obesity. Peptides. 2023.
  2. Lafferty RA, et al. Proglucagon-Derived Peptides as Therapeutics. Front Endocrinol (Lausanne). 2021.
  3. Abdul Fasi M. Patent landscape and therapeutic evolution of mazdutide: a dual GLP-1/Glucagon receptor agonist for obesity and type 2 diabetes. Expert Opin Ther Pat. 2026.

Questions

Where can I buy Mazdutide in bulk?

US Peptide Distributors supplies Mazdutide to approved business buyers. Apply for a buyer account to see wholesale pricing by supply option (USA stock, USA-synthesized or overseas-sourced). There is no minimum order on USA stock, and larger volumes are quoted on request.

Is Mazdutide sold for use in humans?

No. US Peptide Distributors sells Mazdutide to approved business buyers for laboratory research use only, not for use in humans.

Is each lot of Mazdutide third-party tested?

Yes. Every lot US Peptide Distributors supplies is tested by an independent third-party laboratory (we use Freedom Diagnostics and ILS Labs): HPLC for purity and mass spectrometry for identity. Lot COAs appear on this page as they are uploaded.